{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:30:11Z","timestamp":1761823811171},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jocn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jocn.2016.05.017","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T15:35:01Z","timestamp":1473435301000},"page":"128-132","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors"],"prefix":"10.1016","volume":"34","author":[{"given":"Iddo","family":"Paldor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona C.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine J.","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2016.05.017_b0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2016.05.017_b0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/nan.12246","article-title":"Diagnostic, prognostic and predictive relevance of molecular markers in gliomas","volume":"41","author":"Brandner","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.jocn.2016.05.017_b0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT testing\u2013the challenges for biomarker-based glioma treatment","volume":"10","author":"Wick","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jocn.2016.05.017_b0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1474-4422(10)70105-8","article-title":"Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers","volume":"9","author":"Jansen","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2016.05.017_b0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0030","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2016.05.017_b0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1227\/01.neu.0000318159.21731.cf","article-title":"Glioma extent of resection and its impact on patient outcome","volume":"62","author":"Sanai","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2016.05.017_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0045","doi-asserted-by":"crossref","first-page":"e63682","DOI":"10.1371\/journal.pone.0063682","article-title":"Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jocn.2016.05.017_b0050","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3171\/2015.5.JNS1577","article-title":"A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas","volume":"124","author":"Lau","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0055","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neurol.2011.07.004","article-title":"Extent of resection influences outcomes for patients with gliomas","volume":"167","author":"Sanai","year":"2011","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.jocn.2016.05.017_b0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3171\/2010.2.JNS091322","article-title":"Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article","volume":"114","author":"Roberts","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/not137","article-title":"Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma","volume":"16","author":"Chaichana","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0075","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3171\/2012.8.JNS12234","article-title":"Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival","volume":"117","author":"Orringer","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00172709","article-title":"Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials","volume":"12","author":"Curran","year":"1992","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11060-012-0926-0","article-title":"Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes","volume":"109","author":"Dziurzynski","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.wneu.2009.06.001","article-title":"Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival?","volume":"73","author":"Allahdini","year":"2010","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ajco.12076","article-title":"Comparison between poor and long-term survivors with glioblastoma: review of an Australian dataset","volume":"10","author":"Field","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0100","first-page":"1245","article-title":"Prognostic factors influencing clinical outcomes of glioblastoma multiforme","volume":"122","author":"Li","year":"2009","journal-title":"Chin Med J"},{"key":"10.1016\/j.jocn.2016.05.017_b0105","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2016.05.017_b0110","doi-asserted-by":"crossref","first-page":"902","DOI":"10.18632\/oncotarget.6433","article-title":"Molecular heterogeneity of glioblastomas; does location matter?","volume":"7","author":"Denicolai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jocn.2016.05.017_b0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ene.12578","article-title":"Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas","volume":"22","author":"Wang","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2016.05.017_b0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/neuonc\/not159","article-title":"IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection","volume":"16","author":"Beiko","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0125","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1200\/JCO.2010.33.8715","article-title":"Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin","volume":"29","author":"Lai","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0130","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3174\/ajnr.A2950","article-title":"Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma","volume":"33","author":"Carrillo","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jocn.2016.05.017_b0135","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3171\/2013.3.JNS122282","article-title":"Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review","volume":"118","author":"Hodges","year":"2013","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2016.05.017_b0140","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jocn.2016.05.017_b0145","doi-asserted-by":"crossref","first-page":"40896","DOI":"10.18632\/oncotarget.5683","article-title":"IDH mutation and MGMT promoter methylation in glioblastoma: Results of a prospective registry","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jocn.2016.05.017_b0150","doi-asserted-by":"crossref","first-page":"e0130596","DOI":"10.1371\/journal.pone.0130596","article-title":"IDH-mutation is a weak predictor of long-term survival in glioblastoma patients","volume":"10","author":"Amelot","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2016.05.017_b0155","doi-asserted-by":"crossref","first-page":"735659","DOI":"10.1155\/2014\/735659","article-title":"Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia","volume":"2014","author":"Polivka","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jocn.2016.05.017_b0160","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2016.05.017_b0165","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4103\/0973-1482.139154","article-title":"Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas","volume":"10","author":"Thotakura","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.jocn.2016.05.017_b0170","doi-asserted-by":"crossref","first-page":"e16146","DOI":"10.1371\/journal.pone.0016146","article-title":"Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM","volume":"6","author":"Shah","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jocn.2016.05.017_b0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-007-0310-x","article-title":"Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach","volume":"115","author":"Capper","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jocn.2016.05.017_b0180","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1158\/1078-0432.CCR-13-0017","article-title":"Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations","volume":"19","author":"Hartmann","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2016.05.017_b0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1748-717X-6-115","article-title":"Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?","volume":"6","author":"Combs","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00432-013-1519-9","article-title":"Correlation of IDH1\/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China","volume":"140","author":"Zhang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jocn.2016.05.017_b0195","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3892\/ol.2014.2013","article-title":"Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms","volume":"7","author":"Qi","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jocn.2016.05.017_b0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10014-014-0211-3","article-title":"Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas","volume":"32","author":"Sonoda","year":"2015","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.jocn.2016.05.017_b0205","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3174\/ajnr.A3253","article-title":"Probabilistic radiographic atlas of glioblastoma phenotypes","volume":"34","author":"Ellingson","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jocn.2016.05.017_b0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-014-1555-6","article-title":"Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas","volume":"120","author":"Wang","year":"2014","journal-title":"J Neurooncol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586816303071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586816303071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T01:36:41Z","timestamp":1692495401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586816303071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":42,"alternative-id":["S0967586816303071"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2016.05.017","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2016.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}